Related Experiment Video
Updated: Aug 8, 2026
10:28
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
Operationalizing Precision Medicine in Drug Development: Predictive Biomarkers, Companion Diagnostics, and Regulatory
Ingrid Holst-Laubjerg1,2, José M A Moreira1
1Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Clinical Pharmacology and Therapeutics
|August 7, 2026
Summary
Precision medicine enhances drug development by identifying likely responders and reducing harm. Integrating predictive biomarkers and companion diagnostics systematically across therapeutic areas is crucial for success.
Area of Science:
- Biopharmaceutical Development
- Translational Medicine
- Regulatory Science
Background:
- Precision medicine integration into drug development is inconsistent outside oncology.
- Barriers include biomarker hypothesis generation, validation, and companion diagnostic development within complex regulatory frameworks (FDA, EMA, IVDR).
Purpose of the Study:
- To present a pragmatic operational framework for incorporating precision medicine into drug development across therapeutic areas.
- To outline structured approaches for biomarker hypothesis generation, evidence development, and clinical trial designs.
- To summarize regulatory and lifecycle considerations for companion diagnostics.
Main Methods:
- Review of existing frameworks and regulatory guidelines.
- Development of a structured operational framework for precision medicine integration.
- Definition of five clinical development scenarios based on biomarker signal strength.
- Summary of regulatory and lifecycle considerations for companion diagnostics.
Main Results:
- A pragmatic framework for integrating precision medicine into drug development.
- Five clinical development scenarios (front-loaded enrichment, precision-medicine-enabled phase II, adaptive phase II, adaptive phase III, back-loaded confirmatory enrichment).
- Illustrative examples from oncology, cardiovascular, and metabolic diseases highlighting challenges and evolving expectations.
Conclusions:
- Treating precision medicine as a core component of drug development improves trial efficiency and commercial viability.
- Early biomarker planning, integrated clinical-diagnostic strategies, and multi-stakeholder collaboration are critical for successful implementation.
- Extending precision medicine to diagnostic, prognostic, safety biomarkers, and digital signatures offers further opportunities.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...